Figure 4.

Analysis of HSC and progenitor populations in leukaemic mice. Data shown was obtained from reconstituted mice without DOX or animals that have been exposed to DOX for 16–18 months. 7AAD, 7-amino-actinomycin D; * p < 0.05; ** p < 0.01; ns, not significant.

1. The bar diagrams depict absolute percentages ± SD of LT- and ST-HSC in the BM of controls (white bars) and leukaemic mice (black bars).

2. Absolute percentages ± SD of CLP cells in the BM from controls (white bar) and leukaemic mice (black bar).

3. Absolute percentages ± SD of CMP, GMP and MEP in the BM from controls (white bar) and leukaemic mice (black bar).

4. Flow cytometric analysis of LT- and ST-HSC from controls (white squares), GFP⁻ (black dots) and GFP⁺ (green dots) leukaemic animals. LT- and ST-HSC frequencies are represented as relative percentage within the 7AAD⁻, GFP^+/−, lineage⁻, c-Kit⁺, Sca1⁺, CD150⁺, CD48⁻, CD34^+/− BM fraction.

5. Flow cytometric analysis of control (white squares) or GFP⁻ (black dots) and GFP⁺ (green dots) CLP obtained from leukamic mice. CLP frequencies are represented as relative percentage within the 7AAD⁻, GFP^+/−, lineage⁻, c-Kit^int, Sca1^int, IL7 receptor α⁺ BM fraction.

6. Flow cytometric analysis of controls (white squares) or GFP⁻ (black dots) and GFP⁺ (green dots) CMP, GMP and MEP obtained from leukaemic mice. CMP are represented as relative percentage of CD34⁺, Fcγ receptor II/III^low, GMP as CD34⁺, Fcγ receptor II/III⁺ and MEP as CD34⁻, Fcγ receptor II/III^low cells within the 7AAD⁻, GFP^+/−, lineage⁻, c-Kit⁺, Sca1⁻, IL7 receptor α⁻ BM fraction.